Last reviewed · How we verify

NCT05869123

Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer

Active, enrolled Phase 1, PHASE2 Last updated 21 November 2024
What this trial tests

Phase 1, PHASE2 trial testing Online adaptive radiotherapy in Uterine Cervical Neoplasm in 17 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 October 2022
Primary endpoint
3 March 2023
3 March 2025

Quick facts

Lead sponsorPeking Union Medical College Hospital
PhasePhase 1, PHASE2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment17
Start date20 October 2022
Primary completion3 March 2023
Estimated completion3 March 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 70, female only, with Uterine Cervical Neoplasm or Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Online adaptive radiotherapy (oART) has demonstrated to be feasible to reduce planning target volume (PTV) margins for postoperative treatment of endometrial and cervical cancer. To explore the value of reduced margins in oART for postoperative treatment of endometrial and cervical cancer, we conducted a prospective clinical trial to determine the clinical efficacy and toxicity of reduced margins.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Prospects for daily online adaptive radiotherapy for cervical cancer: Auto-contouring evaluation and dosimetric outcomes.
    Zhang Y, Wang G, Chang Y, Wang Z, et al · · 2024 · cited 8× · PMID 38212767 · DOI 10.1186/s13014-024-02398-6

Verify or expand the search:

Other trials of Online adaptive radiotherapy

Trials testing the same drug.

Other recruiting trials for Uterine Cervical Neoplasm

Currently open trials in the same condition.

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05869123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing